Sidley represented Medicxi, a life sciences investment firm, in its US$40 million investment in D3 Bio, a biotechnology company based in China.
The investment will accelerate the development of D3 Bio’s pipeline of oncology compounds, particularly its lead asset, DS3-001.
The Sidley team was led by partner Ruchun Ji, who was supported by senior managing associate Jing Peng and managing associate Jean Qiu.
Sidley’s Global Life Sciences practice, which comprises more than 200 dedicated lawyers globally, offers cross-disciplinary, full-service solutions for life science clients, including M&A and private equity, licensing and collaboration transactions, capital markets, regulatory compliance and enforcement, and dispute resolutions, assisting biotech and pharmaceutical clients around the world. Sidley’s China Life Sciences practice, an integral part of the firm’s Global Life Sciences practice, is the only Band One international firm ranked by Chambers Asia Pacific/Greater China Region for 15 consecutive years.
